Grifols (GIFLF) Cash from Restructuring (2022 - 2023)
Grifols (GIFLF) reported Cash from Restructuring of $171022.8 for Q4 2023, up 364.68% on a YoY basis from $36804.4 in Q4 2022, and up 364.68% quarter-over-quarter from $36804.4 in Q4 2022.
Grifols (GIFLF) Cash from Restructuring (2022 - 2023) Analysis & Trends
Grifols has reported Cash from Restructuring for 2 years, with the latest figure at $171022.8 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn |
| 10 | Grifols | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 171,022.80 |
| Dec 31, 2022 | 36,804.40 |